Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Rocket Pharmaceuticals (RCKT) over the last 6 years, with Dec 2024 value amounting to -$2.73.

  • Rocket Pharmaceuticals' EPS (Weighted Average and Diluted) rose 36.62% to -$0.45 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.25, marking a year-over-year increase of 17.58%. This contributed to the annual value of -$2.73 for FY2024, which is 6.51% up from last year.
  • Rocket Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to -$2.73 in FY2024, which was up 6.51% from -$2.92 recorded in FY2023.
  • In the past 5 years, Rocket Pharmaceuticals' EPS (Weighted Average and Diluted) registered a high of -$2.52 during FY2020, and its lowest value of -$3.26 during FY2022.
  • Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$2.92 (2023), whereas its average is -$2.97.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first crashed by 59.49% in 2020, then climbed by 10.43% in 2023.
  • Rocket Pharmaceuticals' EPS (Weighted Average and Diluted) (Yearly) stood at -$2.52 in 2020, then dropped by 5.95% to -$2.67 in 2021, then fell by 22.10% to -$3.26 in 2022, then rose by 10.43% to -$2.92 in 2023, then climbed by 6.51% to -$2.73 in 2024.